ReNeuron Group (ReNeuron Group) Gross-Profit-to-Asset % : 3.95% (As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ReNeuron Group's annualized Gross Profit for the quarter that ended in Sep. 2023 was $0.39 Mil. ReNeuron Group's average Total Assets over the quarter that ended in Sep. 2023 was $9.83 Mil. Therefore, ReNeuron Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 3.95%.

ReNeuron Group Gross-Profit-to-Asset % Historical Data

The historical data trend for ReNeuron Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.13

22.50

1.18

1.83

3.72

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															0.50	3.48	5.16	1.64	3.95

Competitive Comparison

For the Biotechnology subindustry, ReNeuron Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Gross-Profit-to-Asset % falls into.

ReNeuron Group Gross-Profit-to-Asset % Calculation

ReNeuron Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0.643	/	( (22.823	+	11.705)	/ 2 )
	=	0.643	/	17.264
	=	3.72 %

ReNeuron Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	0.388	/	( (11.705	+	7.949)	/ 2 )
	=	0.388	/	9.827
	=	3.95 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

ReNeuron Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.